Publications by authors named "Casper van Olden"
Cellular senescence is an essentially irreversible growth arrest that occurs in response to various cellular stressors and may contribute to development of type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). In this article, we investigated whether chronically elevated insulin levels are associated with cellular senescence in the human liver. In 107 individuals undergoing bariatric surgery, hepatic senescence markers were assessed by immunohistochemistry as well as transcriptomics.
View Article and Find Full Text PDFArticle Synopsis
- - This clinical trial assessed the effectiveness of the HDL mimetic CER-001 in patients with very low levels of HDL cholesterol, aiming to see if it could help reduce atherosclerosis as previous trials had not shown results in patients with normal HDL levels.
- - 30 patients with familial hypoalphalipoproteinemia were treated with either CER-001 or a placebo over 24 weeks, with evaluations using advanced imaging techniques to measure changes in artery wall size and inflammation.
- - Results showed no significant difference in vessel wall size or inflammation between the treatment and placebo groups after 24 weeks, indicating that CER-001 did not provide the expected benefits in this specific patient population.
Purpose: The contribution of intestinal bacterial strains (gut microbiota) in human metabolism and obesity is being increasingly recognized. The goal of this article was to provide a commentary on the clinical usefulness of these data.
Methods: We performed a review of the currently available articles on PubMed.
The term 'therapeutic angiogenesis' originated almost two decades ago, following evidence that factors that promote blood vessel formation could be delivered to ischaemic tissues and restore blood flow. Following this proof-of-principle, safety and efficacy of the best-studied angiogenic factors (eg, vascular endothelial growth factor) were demonstrated in early clinical studies. Promising results led to the development of larger controlled trials that, unfortunately, have failed to satisfy the initial expectations of therapeutic angiogenesis for ischaemic heart disease.
View Article and Find Full Text PDF